Skip to main content

Combination therapy with the broadly neutralizing antibody VRC07-523LS and the latency reversal agent Vorinostat fails to substantially reduce latent, resting CD4+T cell infection or reduce low-level viremia

Publication ,  Conference
Margolis, DM; James, KS; Tuyishime, M; Falcinelli, SD; Joseph, SB; Allard, B; Kirchherr, JL; Clohosey, M; Gorelick, RJ; Gama, L; Koup, RA ...
Published in: JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
2021

Duke Scholars

Published In

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY

EISSN

1758-2652

Publication Date

2021

Volume

24

Start / End Page

69 / 69

Related Subject Headings

  • 4206 Public health
  • 4202 Epidemiology
  • 3202 Clinical sciences
  • 1199 Other Medical and Health Sciences
  • 1117 Public Health and Health Services
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Margolis, D. M., James, K. S., Tuyishime, M., Falcinelli, S. D., Joseph, S. B., Allard, B., … Gay, C. L. (2021). Combination therapy with the broadly neutralizing antibody VRC07-523LS and the latency reversal agent Vorinostat fails to substantially reduce latent, resting CD4+T cell infection or reduce low-level viremia. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY (Vol. 24, pp. 69–69).
Margolis, D. M., K. S. James, M. Tuyishime, S. D. Falcinelli, S. B. Joseph, B. Allard, J. L. Kirchherr, et al. “Combination therapy with the broadly neutralizing antibody VRC07-523LS and the latency reversal agent Vorinostat fails to substantially reduce latent, resting CD4+T cell infection or reduce low-level viremia.” In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 24:69–69, 2021.
Margolis DM, James KS, Tuyishime M, Falcinelli SD, Joseph SB, Allard B, et al. Combination therapy with the broadly neutralizing antibody VRC07-523LS and the latency reversal agent Vorinostat fails to substantially reduce latent, resting CD4+T cell infection or reduce low-level viremia. In: JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. 2021. p. 69–69.
Margolis DM, James KS, Tuyishime M, Falcinelli SD, Joseph SB, Allard B, Kirchherr JL, Clohosey M, Gorelick RJ, Gama L, Koup RA, Mascola JR, Floris-Moore M, Ferrari G, Eron JJ, Kuruc JD, Archin NM, Gay CL. Combination therapy with the broadly neutralizing antibody VRC07-523LS and the latency reversal agent Vorinostat fails to substantially reduce latent, resting CD4+T cell infection or reduce low-level viremia. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. 2021. p. 69–69.

Published In

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY

EISSN

1758-2652

Publication Date

2021

Volume

24

Start / End Page

69 / 69

Related Subject Headings

  • 4206 Public health
  • 4202 Epidemiology
  • 3202 Clinical sciences
  • 1199 Other Medical and Health Sciences
  • 1117 Public Health and Health Services
  • 1103 Clinical Sciences